OBJECTIVES: To describe a pharmacist-led diabetes prevention service piloted within an employer-based wellness program. PRACTICE DESCRIPTION: A pharmacist-led ambulatory care clinic within a school of pharmacy that provides wellness services to university employees. PRACTICE INNOVATION: Implementation of a diabetes prevention service using opportunistic A1C screening within a biometric screening program. Patients with a prediabetes-level A1C from July 2016 to March 2019 were invited to participate in the National Diabetes Prevention Program (NDPP). EVALUATION: Comparison of baseline characteristics of participants with normal and elevated A1C. Evaluation of participation in the NDPP and changes in clinical values at the subsequent biometric screening appointment for individuals with a prediabetes-level AlC. RESULTS: A1C testing of 740 individuals identified 69 participants (9.3%) with a prediabetes-level A1C and 7 (1.0%) with a diabetes-level A1C. Compared with those with a normal A1C (< 5.7%), participants with an elevated A1C were more likely to be older, nonwhite, obese, and physically inactive, to have a sibling with diabetes, higher random blood sugar (RBS), lower high-density lipoprotein (HDL), and more likely to have hypertension. Twelve patients participated in the NDPP, although most attended only 1 session. Attenders had a significantly lower baseline weight and body mass index (BMI). There were no significant differences in the changes in A1C, BMI, weight, RBS, or HDL between attenders and nonattenders approximately 1 year later. CONCLUSION: This pilot demonstrated that opportunistic A1C testing could be incorporated into an ambulatory care clinic within a pharmacist-led employer-based wellness program. Uptake and retention of the NDPP were poor. Barriers to NDPP participation need to be investigated and addressed to improve service impact.
OBJECTIVES: To describe a pharmacist-led diabetes prevention service piloted within an employer-based wellness program. PRACTICE DESCRIPTION: A pharmacist-led ambulatory care clinic within a school of pharmacy that provides wellness services to university employees. PRACTICE INNOVATION: Implementation of a diabetes prevention service using opportunistic A1C screening within a biometric screening program. Patients with a prediabetes-level A1C from July 2016 to March 2019 were invited to participate in the National Diabetes Prevention Program (NDPP). EVALUATION: Comparison of baseline characteristics of participants with normal and elevated A1C. Evaluation of participation in the NDPP and changes in clinical values at the subsequent biometric screening appointment for individuals with a prediabetes-level AlC. RESULTS:A1C testing of 740 individuals identified 69 participants (9.3%) with a prediabetes-level A1C and 7 (1.0%) with a diabetes-level A1C. Compared with those with a normal A1C (< 5.7%), participants with an elevated A1C were more likely to be older, nonwhite, obese, and physically inactive, to have a sibling with diabetes, higher random blood sugar (RBS), lower high-density lipoprotein (HDL), and more likely to have hypertension. Twelve patients participated in the NDPP, although most attended only 1 session. Attenders had a significantly lower baseline weight and body mass index (BMI). There were no significant differences in the changes in A1C, BMI, weight, RBS, or HDL between attenders and nonattenders approximately 1 year later. CONCLUSION: This pilot demonstrated that opportunistic A1C testing could be incorporated into an ambulatory care clinic within a pharmacist-led employer-based wellness program. Uptake and retention of the NDPP were poor. Barriers to NDPP participation need to be investigated and addressed to improve service impact.
Authors: Lubna Al-Ansary; Andrew Farmer; Jennifer Hirst; Nia Roberts; Paul Glasziou; Rafael Perera; Christopher P Price Journal: Clin Chem Date: 2011-03-02 Impact factor: 8.327
Authors: Symen Ligthart; Thijs T W van Herpt; Maarten J G Leening; Maryam Kavousi; Albert Hofman; Bruno H C Stricker; Mandy van Hoek; Eric J G Sijbrands; Oscar H Franco; Abbas Dehghan Journal: Lancet Diabetes Endocrinol Date: 2015-11-11 Impact factor: 32.069
Authors: Anita D Misra-Hebert; Bo Hu; Glen Taksler; Robert Zimmerman; Michael B Rothberg Journal: J Gen Intern Med Date: 2016-04-11 Impact factor: 5.128
Authors: Sara R Adams; Deanne M Wiley; Andromache Fargeix; Victoria George; Romain S Neugebauer; Julie A Schmittdiel Journal: J Occup Environ Med Date: 2015-11 Impact factor: 2.162
Authors: Kai McKeever Bullard; Mohammed K Ali; Giuseppina Imperatore; Linda S Geiss; Sharon H Saydah; Jeanine B Albu; Catherine C Cowie; Nancy Sohler; Ann Albright; Edward W Gregg Journal: PLoS One Date: 2015-04-30 Impact factor: 3.240
Authors: Anne Rongen; Suzan J W Robroek; Wouter van Ginkel; Dennis Lindeboom; Bibiëlle Altink; Alex Burdorf Journal: BMC Public Health Date: 2014-06-09 Impact factor: 3.295
Authors: Courtney E Gamston; Anna N Kirby; Richard A Hansen; David T Redden; Heather P Whitley; Courtney Hanson; Kimberly B Lloyd Journal: J Am Pharm Assoc (2003) Date: 2019-12-27